A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc.
Centre hospitalier de l'Université de Montréal (CHUM)
Ohio State University Comprehensive Cancer Center
University of Colorado, Denver
University of Nebraska
Institut du Cancer de Montpellier - Val d'Aurelle
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Sahlgrenska University Hospital
Institut Bergonié
University of California, San Francisco
Esperas Pharma Inc.
Stanford University
Ohio State University Comprehensive Cancer Center
Mayo Clinic
Universitat Jaume I
Stanford University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Jules Bordet Institute
University of Aarhus
Assiut University
Dublin City University
Institut de cancérologie Strasbourg Europe
Charite University, Berlin, Germany
Charite University, Berlin, Germany
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
St Vincent's University Hospital, Ireland
Glasgow Royal Infirmary
University of Southampton
Institut de Cancérologie de Lorraine
Weprom
Jerome Canady Research Institute for Advanced Biological & Technological Sciences
Oslo University Hospital
Ohio State University Comprehensive Cancer Center
Imperial College London
Abramson Cancer Center at Penn Medicine
City of Hope Medical Center
Imperial College London
Instituto do Cancer do Estado de São Paulo
Swiss Cancer Institute
CureOne
University of Iowa
Ohio State University Comprehensive Cancer Center
Johns Hopkins Bloomberg School of Public Health
Washington University School of Medicine
Wake Forest University Health Sciences
Johns Hopkins Bloomberg School of Public Health
UNICANCER
Alliance for Clinical Trials in Oncology